Food and Drug Administration (FDA)USASource updated: May 29, 2026

Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)

Covidien (Medtronic) recalls specific lots of MonaTherm probes due to potential incorrect temperature readings or quality defects.

Primary source: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm

PV Impact Brief

Urgency: HighConfidence: high

What changed

FDA classified the Covidien MonaTherm probe recall as Class 2 and instructed users to quarantine and return unused products.

Why it matters

Incorrect temperature readings could lead to misdiagnosis or inappropriate patient management, posing serious safety risks.

Action needed

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Relevant for: Regulatory Intelligence LeadSignal Management Lead
Processes impacted: Signal ManagementLabeling
Owner: Regulatory Intelligence Lead
Review cadence: single event

Regulatory action details

Action type: Class 2 Device Recall
Publication date: 2026-06-04
Safety issue: The system may sporadically display a 0 x-ray dose administered to the patient during fluoroscopy and/or single-frame acquisitions, even though an actual x-ray dose is being applied.

Affected products

ARTIS pheno interventional fluoroscopic x-ray system
Siemens Medical Solutions USA, Inc

PV internal implications

Distribution of Customer Advisory Notice (CAN) to all affected customers.

View regulator source

Evidence and confidence

Confidence: highSource updated: May 29, 2026

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfmUpdated May 29, 2026

Full briefing

Practical implication

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

The FDA announced a Class 2 recall by Covidien (Medtronic) for MonaTherm General Purpose Temperature Probe, lot Z-2273-2026. Users must quarantine and return unused products.

What changed: FDA classified the Covidien MonaTherm probe recall as Class 2 and instructed users to quarantine and return unused products.

Why it matters: Incorrect temperature readings could lead to misdiagnosis or inappropriate patient management, posing serious safety risks.

Practical implication: Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals #Recall #FDA #safety_signal #firecrawl-agent #regulatory-extraction

Related updates for your role

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, Signal Management Lead

verifiedRegulatory action: Draft Guidance

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Checklist

Read impact briefarrow_forward

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Updated eCTD v4.0 technical validation criteria

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Country ComplianceICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Technical Guidance

Read impact briefarrow_forward

publicHealth Canada · Canada · Updated Jul 15, 2026

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV

verifiedRegulatory action: Draft Guidance

Read impact briefarrow_forward